Sirolimus (Rapamune®)
Sirolimus (Rapamune®) is a pharmaceutical drug with 7 clinical trials. Currently 3 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
2 of 4 finished
50.0%
2 ended early
3
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Systematic Approach for Children With Orbital Malformation With Sirolimus Use
Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
Clinical Trials (7)
Systematic Approach for Children With Orbital Malformation With Sirolimus Use
Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
Study Evaluating Rapamune® Maintenance Regimen
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7